The Judicial Panel on Multidistrict Litigation centralized the ByHeart infant formula cases on April 2, transferring 19 actions to the Southern District of New York and assigning the docket to Judge Arun S. Subramanian as MDL 3178 — In re: ByHeart, Inc., Infant Formula Marketing, Sales Practices, and Products Liability Litigation. Nine of the actions allege that infants became seriously ill with botulism after being fed ByHeart formula; the other ten are putative nationwide and statewide class actions asserting economic injuries on behalf of purchasers. Every responding party supported centralization.
Measure the timeline against the torts this publication usually covers. ByHeart announced a voluntary recall of two batches of its Whole Nutrition Infant Formula on November 8, 2025, after the FDA flagged an ongoing infant botulism investigation. By November 11 the recall covered every ByHeart product on the market, cans and single-serve sticks alike. Personal injury complaints started landing in December and January across multiple districts, a group of plaintiffs moved the JPML in January, and by the first week of April the docket was centralized. Recall to MDL in under five months. Hair relaxer took the better part of a year from the Sister Study to MDL 3060; the latency torts take decades to form at all.
Why this one moved so fast
Speed here is a function of the injury profile. Infant botulism is acute: onset follows exposure by days or weeks, not decades, and the CDC and FDA ran a joint outbreak investigation in real time. Reporting during the outbreak put the count at dozens of hospitalized infants across a wide multistate footprint before new cases tapered off in late December — and public-health experts described it as the first U.S. infant botulism outbreak ever linked to formula. There is no war over latency, no dueling epidemiologists arguing about confounders across a twenty-year exposure window. The causation record is an outbreak curve with a recall date on it.
That does not make the cases simple. Because nothing like this has happened before, there is no litigation template — no prior formula-botulism verdicts, no established damages benchmarks for an injury that hospitalizes infants and can require months of supportive care. And ByHeart has a defense narrative in progress: the company noted that no product tested positive for Clostridium botulinum when the recall issued and has framed the recall as precautionary. Plaintiffs will answer with the 2023 FDA warning letter citing significant violations at a company facility — issues ByHeart says were addressed, at a plant it says was not involved in producing the recalled lots. Root cause, manufacturing process, and regulatory compliance are exactly the common questions the Panel cited in centralizing.
The hybrid structure is the procedural story
MDL 3178 puts serious-injury infant cases and purchaser economic-loss classes in front of the same judge. That is efficient for discovery — one root-cause record serves both tracks — but it creates a sequencing question that will shape settlement architecture. Class certification briefing on the economic claims and expert admissibility on the injury claims will run through the same courtroom, and rulings on one track reprice the other. A certified purchaser class gives plaintiffs leverage and ByHeart a vehicle for global peace on the cheap end of the docket; the injury inventory is where the real exposure sits.
Single-defendant economics
The underwriting profile is the inverse of a PFAS or asbestos docket. There is one defendant, a venture-backed formula startup, not a roster of Fortune 500 co-defendants with decades of insurance towers. In single-defendant food cases, available coverage tends to define the recovery ceiling, and the practical questions for firms evaluating inventory are policy limits, excess layers, and the company's ability to fund a resolution — not which of eight defendants to prioritize. The claimant pool is also bounded by the outbreak itself: this is a finite docket with a knowable population, not an open-ended tort that recruits for a decade.
For intake operations, that means the window is compressed on both ends. The injured population is small and largely identified through the public-health investigation, the filing pace has already been set by the December-through-March wave, and the coordinated proceeding now controls the calendar. Firms treating this like a long-tail acquisition campaign are solving the wrong problem. The docket to watch is Judge Subramanian's initial case management structure — how he sequences the class and injury tracks will say more about resolution timing than any filing count. For where this sits in the broader 2026 landscape, see the 2026 mass tort map.